Profiel
David Dornan is Chief Scientific Officer at Whitehawk Therapeutics, Inc. since 2025.
Former roles include Chief Scientific Officer at Elevation Oncology, Inc. from 2022 to 2025, Senior Vice President-Research & Manufacturing at Bolt Biotherapeutics, Inc. from 2019 to 2022, and Director & Head-Oncology Research at Gilead Sciences, Inc. from 2012 to 2017.
Education includes a doctorate from the University Of Dundee and an undergraduate degree from the University of Strathclyde.
Actieve functies van David Dornan
| Bedrijven | Functie | Begin |
|---|---|---|
| WHITEHAWK THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 18-02-2025 |
Eerdere bekende functies van David Dornan
| Bedrijven | Functie | Einde |
|---|---|---|
| ELEN ONCO | Hoofd Techniek/Wetenschap/O&O | 17-02-2025 |
| BOLT BIOTHERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 11-03-2022 |
| GILEAD SCIENCES, INC. | Directeur/Bestuurslid | 01-11-2017 |
Opleiding van David Dornan
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
University Of Dundee
University Of Dundee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Elevation Oncology, Inc.
Elevation Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops elevating precision medicines for cancer treatment | Health Technology |
Aadi Bioscience, Inc.
Aadi Bioscience, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
















